Introduction
Cytogenetics have for 20 years been recognized as an important prognostic factor for patients with myelodysplastic syndromes (MDS). 1 The independent prognostic significance of cytogenetics has since been confirmed in several large patient series. [2] [3] [4] Moreover, several series of patients undergoing allogeneic hematopoietic SCT have confirmed that cytogenetics retain their prognostic importance after SCT for patients with MDS or AML arising from MDS. [5] [6] [7] At present, the most commonly used cytogenetics risk grouping scheme is that of the International Prognostic Scoring System (IPSS) 2 (which also forms part of the newer WHO Prognostic Scoring System (WPSS) 8 ), although refinements of this scheme have recently been proposed. 3, 4, 9 However, all of the patient cohorts on whom those schemes are based were treated primarily with supportive care (or only followed up to the time of aggressive therapy 9 ). Therefore, those schemes may not be optimal for patients who undergo SCT. Indeed, the success of SCT relies in part on an immunological graft vs tumor effect; sensitivity of the tumor cells to this effect may not correlate directly with their behavior in untreated disease or even with their sensitivity to conventional chemotherapy. A cytogenetics grouping scheme derived from a cohort of transplanted patients may then differ from the existing schemes, and may allow better prognostication and stratification of patients who undergo SCT. This is likely to be of growing importance, as SCT is at present the only modality with curative potential in MDS, and, with the advent of reduced intensity conditioning, is being used for patients with MDS who are older or have a higher co-morbid burden.
We have previously proposed an SCT-specific cytogenetics grouping scheme, based on a retrospective study of the DFCI/BWH (Dana-Farber Cancer Institute/Brigham and Women's Hospital) patients. 10 In this scheme, patients with abnormalities of chromosome 7 or complex karyotype are considered 'adverse risk', whereas all others are considered 'standard risk'. This scheme had a strong prognostic relevance in our cohort, regardless of disease type, stage and conditioning regimen intensity. It had better stratification ability for patients with AML arising from MDS than any of the existing AML grouping schemes, arguing that cytogenetics risk assignment for those patients should be based on an MDS-specific scheme rather than an AML-specific scheme. This is relevant, as the WHO classification 11 categorizes those patients as AML (including patients formerly categorized as having refractory anemia with excess blasts in transformation (RAEB-t)), without addressing the question of how best to characterize their cytogenetics for prognostic purposes. Moreover, we showed that patients with therapy-related disease had a prognosis after SCT similar to that of patients with de novo disease, after adjusting for cytogenetics risk, as was also reported by the Seattle group. 7 In this study, we report the multicenter validation of these findings in an independent large cohort of patients from three separate transplantation centers.
Materials and methods

Patients
We analyzed data on 546 adult patients with MDS who underwent Allo-SCT at the Fred Hutchinson Cancer Research Center (FHCRC) or the MD Anderson Cancer Center (MDACC) between 1996 and 2007, or at Princess Margaret Hospital (PMH) between 2001 and 2007. We included patients with AML who had an earlier diagnosis of MDS (considered as 'AML with MDS-related changes' under the 2008 WHO classification 11 ) and patients with 20-30% marrow blasts (formerly characterized as RAEBt); these two groups are collectively referred to herein as 'AML/MDS'. We excluded patients who had received an earlier stem cell transplant, whether autologous or allogeneic, unless they had received an autologous transplant for a disease other than MDS or AML (that is, for patients with therapy-related MDS/AML). A total of 93 patients, who had received alkylating agent chemotherapy, a topoisomerase II inhibitor or radiotherapy, at least 1 year before the diagnosis of MDS, were categorized as having 'therapyrelated disease', as opposed to the remaining 453 patients with 'de novo disease'. Cytogenetics was obtained from the medical records. For patients with evidence of cytogenetics evolution, the latest karyotype before SCT was used for the analysis.
IRB approval was obtained from all the participating institutions to perform this study, in accordance with the principles of the Declaration of Helsinki.
Treatment
Transplantation protocols, as expected, varied by transplantation center. Two-thirds of patients received a conventional intensity conditioning regimen, which included TBI in 30% of patients. A lower proportion of MDACC patients received a conventional intensity regimen (21% compared with 77% for FHCRC and 68% for PMH, Po0.0001); conventional intensity regimens at MDACC were all based on fludarabine þ melphalan, whereas patients at FHCRC and PMH received mostly CY þ TBI or CY þ BU for conventional intensity SCT.
Among the patients who received a reduced intensity regimen, 42% received low-dose TBI as part of their conditioning. In total, 65% of patients received PBPCs as a source of stem cells. The donors were HLA-identical siblings for 46% of patients, matched unrelated donors for 36%, and HLA-mismatched donors (related or unrelated) in the remaining 18%. GVHD prophylaxis consisted mostly of a calcineurin inhibitor (CYA or tacrolimus) combined with MTX (73%) or CYA with mycophenolate mofetil (12%).
Statistics
Patient baseline characteristics were treated descriptively. OS and relapse-free survival (RFS) were calculated using the Kaplan-Meier method. OS was defined as the time from stem cell infusion to death from any cause. Patients who were alive or lost to follow-up were censored at the time last seen alive. RFS was defined as the time from stem cell infusion to relapse or death from any cause. Patients who were alive without relapse were censored at the time last seen alive and relapse free. The log-rank test was used for comparisons of Kaplan-Meier curves. Cumulative incidence curves for non-relapse death and relapse with or without death were constructed reflecting time to relapse and time to non-relapse death as competing risks. The difference between cumulative incidence curves in the presence of a competing risk was tested using the Gray method. 12 Time to relapse and time to non-relapse death were measured from the date of stem cell infusion. Potential prognostic factors for survival, RFS, relapse and nonrelapse death were examined in the proportional hazards model, as well as in the competing risks regression model. 13 All interaction terms including interaction with time were examined in the proportional hazards regression model. Proportional hazards assumptions for all important variables were examined. For our analysis of AML/MDS patients, we compared model fit using various classification options by comparing the Akaike Information Criterion (AIC) between models. All calculations were done using SAS 9.2 (SAS Institute Inc, Cary, NC, USA) and R (version 2.5.1).
Results
Patient characteristics and cytogenetics
The baseline demographic and clinical characteristics of the 546 patients enrolled in this study are presented in Table 1 . The median age for the entire cohort was 53 (range, 18-74) years. Patients transplanted at MDACC were on average older (median age 59 vs 52 years for FHCRC and 53 years for PMH, Po0.0001). In total, 58% of the patients had MDS (as defined by the WHO criteria 14 ); among them, 30% had low-risk MDS (including refractory anemia with or without ringed sideroblasts, refractory cytopenias with multilineage dysplasia with or without ringed sideroblasts) and 27% had high-risk MDS (refractory anemia with excess blasts (RAEB-1 or RAEB-2)). The eight patients with chronic myelomonocytic leukemia were classified as low-risk, based on a comparison of their outcome with the low-risk and high-risk groups. A total of 39% of patients had AML and an earlier diagnosis of MDS, and 4% had AML but would previously have been classified as having RAEB-t. A total of 17% of patients were considered to have therapy-related disease. Most of the patients (61%) were transplanted without having received pre-SCT therapy; 13% were transplanted in CR; the remaining 26% were transplanted with active disease (10% in PR, 5% after induction failure and 10% with active relapsed disease). Patients from MDACC more frequently had advanced stage disease at SCT (68 vs 8% for FHCRC and 9% for PMH, Po0.0001). The median time from diagnosis to transplantation was 7 (range, 0-634) months. Patients from MDACC tended to be transplanted farther from diagnosis (after a median of 13 months, compared with 7 months for FHCRC and 5 months for PMH, Po0.0001). The followup for survivors was 6-135 (median 48) months. Table 2 details pre-transplantation cytogenetics findings for all patients. Data were available in 86% of patients; for the remaining 14%, cytogenetics had either not been obtained or the results were not available. Among all patients, when grouped according to the IPSS/WPSS scheme, 40% had favorable, 21% had intermediate and 24% had adverse cytogenetics. There was no significant difference between the three centers in the proportions of patients in each cytogenetics group. The most common finding was a normal karyotype (32% of patients). The patients with unavailable cytogenetics had significantly worse OS, with 4-year OS of 27 vs 40% for patients with available cytogenetics data (P ¼ 0.007). However, patients without cytogenetics information tended to be transplanted in the earlier years of the study (P ¼ 0.02), which could have confounded the results. Indeed, in a proportional hazards model including both availability of cytogenetics and year of transplantation, availability of cytogenetics data lost its prognostic significance (hazard ratio (HR) ¼ 0.97, P ¼ NS). Those patients were not further considered in the subsequent analyses. As expected, patients with therapy-related disease more often had poor-risk cytogenetics. Only 30% of patients with therapy-related disease had favorable cytogenetics, compared with 51% of patients with de novo disease (P ¼ 0.0007); 21% of patients with therapy-related disease had intermediate cytogenetics, compared with 26% of patients with de novo disease (P ¼ 0.5) and 49% of patients with therapy-related disease had poor-risk cytogenetics, compared with 24% of patients with de novo disease (Po0.0001) (see Table 2 ).
Patients with adverse cytogenetics tended to be transplanted earlier in the course of their disease (median time from diagnosis to SCT: 6 months compared with 8 months for patients with intermediate or favorable cytogenetics, Po0.0001). This was true even after stratifying for stage of disease at SCT (not shown).
Derivation of the cytogenetics risk groups
The 4-year OS and RFS for the entire cohort were 40% (95% confidence interval (CI), 35-44%) and 36% (CI, 31-40%), respectively. Cytogenetics (classified according to the IPSS/WPSS scheme), along with transplantation center and all the baseline variables from Table 1 (except for earlier autologous transplantation for patients with therapy-related disease, given the small sample size), were entered into a proportional hazards model for OS. As graft source and GVHD prophylaxis regimens violated proportional hazards assumptions, but were not significantly associated with outcome (not shown), the models were stratified on those two variables. Among the remaining variables, cytogenetics, disease type and stage, and year of transplantation were significant for outcome. On the basis of the results of the models, disease was dichotomized into 'early stage' (untreated patients and patients in CR) and 'advanced stage' (patients with induction failure, PR or active relapse at the time of transplantation). Age was dichotomized with a cutoff of 50 years, although it was not a significant prognostic factor regardless of the cutoff chosen. For RFS, the same variables were significant, except for the year of transplantation, which showed only a trend toward significance. Those variables were then included in a multivariable model with each cytogenetics abnormality entered as a separate term. The results are given in Table 3 . Two distinct prognostic groups can be clearly separated: an 'adverse-risk' group comprising any abnormality of chromosome 7 and complex karyotypes (X3 abnormalities) and a 'standard-risk' group comprising all other abnormalities, including normal karyotype, del(5q) and del(20q) (which are considered favorable in the IPSS/WPSS scheme). This grouping system is identical to the one that we proposed earlier based on our DFCI/ BWH data. 10 We also analyzed the impact of monosomy-containing karyotypes, as those have been associated with adverse prognosis in AML. 15 In our cohort, there were 47 instances of non-complex karyotypes containing a monosomy abnormality. Of those, 9 did not involve chromosome 7, and of those only 3 had isolated monosomy karyotypes (including 2 with monosomy Y). A non-7 monosomycontaining karyotype seemed to be associated with worse OS after transplantation (HR ¼ 2.6, P ¼ 0.013); however, there was no significant adverse prognosis for isolated non-7 monosomy karyotypes. The small number of patients involved, however, precluded reliable conclusions.
Survival, relapse and non-relapse mortality
The 4-year OS for patients in the standard-risk cytogenetics group was 46% (CI, 40-52%), compared with 23% (CI, 16-30%) in the adverse-risk group (Po0.0001). The corresponding figures for RFS were 42% (CI, 36-47%) vs 21% (CI, 14-28%) (Po0.0001). The 4-year cumulative incidence of relapse in the standard-risk cytogenetics group was 22% (CI, 17-27%) compared with 41% in the adverserisk group (CI, 33-50%) (Po0.0001), whereas the cumulative incidence of non-relapse mortality (NRM) was 36% (CI, 31-42%) vs 38% (CI, 29-46%) (P ¼ 0.4). The corresponding curves are shown in Figure 1 .
We repeated the multivariable analyses for OS and RFS using the new cytogenetics grouping scheme. We also built regression models for relapse and NRM. The results are shown in Table 4 . Adverse cytogenetics, as defined in the previous section, was associated with a HR for mortality of 2.2 (Po0.0001), and a similar HR for death or relapse, compared with standard-risk cytogenetics. This difference was due to an increased risk of relapse (HR for relapse 2.0, P ¼ 0.0004) without a significant effect on NRM (HR ¼ 1.4, P ¼ 0.07). As before, disease type and stage, as well as the year of transplantation were significant factors for OS. We then examined the prognostic significance of our cytogenetics grouping scheme in various patient subgroups. The results (not shown) show that cytogenetics retained their prognostic relevance regardless of patient age (o50 or X50), disease type (MDS or AML/MDS), conditioning regimen intensity (conventional or reduced intensity) or receipt of earlier leukemogenic therapy. Within each subgroup, patients with adverse cytogenetics had significantly worse OS (all Pp0.01). In fact, there was no significant interaction between cytogenetics risk group and any of the other variables in the proportional hazards model.
To summarize the outcomes of various patient subgroups stratified by cytogenetics, we merged the present cohort with the original DFCI/BWH cohort of 227 patients in which the scheme was originally derived. 10 The OS and RFS within each subgroup are shown in Table 5 .
Classification of cytogenetics for patients with AML/MDS
As it is not known whether patients with AML/MDS (including patients with AML and an earlier diagnosis of MDS, and patients formerly characterized as having RAEB-t) should be classified as MDS patients or as AML patients with respect to cytogenetics, we sought to determine the optimal grouping scheme for this patient group in our cohort. We built a proportional hazards model for OS for only those 233 patients, and compared the model fit (based on Akaike's Information Criterion (AIC), with a lower score indicating a better model fit). The AIC for our proposed scheme (AIC ¼ 2089) was lower than the AIC using the MRC grouping scheme for AML 16 (AIC ¼ 2090), the CALGB scheme 17 (AIC ¼ 2106), the SWOG/ECOG scheme 18 (AIC ¼ 2097) or our previously proposed AML grouping scheme 10 (AIC ¼ 2093) ). This argues that cytogenetics for those patients are better characterized according to our MDS-specific scheme than according to an AML-specific one. Using our proposed scheme, the HR associated with adverse cytogenetics for this patient subgroup was 2.2 (Po0.0001).
Discussion
In a previous study of data from 227 patients transplanted at DFCI/BWH, we proposed a cytogenetics grouping scheme specifically applicable to patients with MDS or AML arising from MDS undergoing SCT. 10 In this study, we performed a similar analysis on an entirely independent, multicenter cohort of 546 patients. We showed not only that our previously proposed scheme allowed prognostic stratification in this new cohort, but that a new grouping scheme derived from scratch led to the identical scheme, which lends strong support to the broad applicability of the Cytogenetics risk groups for MDS after SCT P Armand et al originally proposed scheme. In the current study, we were also able to further refine the scheme by classifying patients with del(5q) or del(20q) in the standard-risk category (which we could not classify in our original study given the limited sample size of those patients). These results confirm that patients with MDS or AML arising from MDS undergoing SCT may be categorized into two distinct risk groups based on their karyotype; patients with abnormalities of chromosome 7 and patients with complex cytoge-netics (X3 abnormalities) have an adverse prognosis compared with all other abnormalities, which have a similar prognosis to patients with normal karyotype. We still had too few patients with monosomy Y to allow reliable classification of this subgroup, although the limited data available suggested that they were best considered standard risk as well.
Our proposed scheme is similar to the IPSS 2 /WPSS 8 scheme. However, the favorable and intermediate categories Figure 2) . The absence of a favorable group is consistent with other transplantation series 6, 7 (although those studies were not designed to establish an optimal grouping scheme, and one of them overlaps with our validation cohort 7 ). In the study of Alessandrino et al., 6 cytogenetics had a significant effect on the risk of relapse (and no significant effect on NRM), without a significant difference between the favorable and intermediate IPSS groups. The same was basically true in the study of Chang et al., 7 although over long follow-up the intermediate-risk cytogenetics group showed more of an intermediate position in its risk of relapse. There is no obvious explanation for this discrepancy; but the study of Chang et al. included the largest sample of patients with therapy-related disease, and may, therefore, have had more power to detect a difference in the relapse rate specific to this population. Even so, in all of those studies, 6,7,10 the RFS and OS were not significantly different between the IPSS favorable and intermediate groups, in agreement with the major conclusion of this study. Several limitations of this analysis deserve comment. First, similar to our earlier report, this was a retrospective study that always carries the potential of selection bias. For example, clinicians may transplant patients with adverse cytogenetics earlier than others (as we observed here), which may narrow the observed difference in outcomes. Second, because of the retrospective nature of this analysis, we did not require central review of primary cytogenetics data, which would be practically and logistically impossible in a multicenter study of this size. However, the large sample size of this study should limit the impact of random errors in the cytogenetics assignment. Third, this study did not make systematic use of FISH (fluorescence in situ hybridization) to detect karyotypically silent abnormalities, in particular del(5q), monosomy 7 or trisomy 8. The rate of karyotypically silent abnormalities detected by FISH varies by series, 19, 20 although it was low in a large study of AML patients. 20 If patients with FISH-detected abnormalities have a similar outcome to those with karyotypically overt ones, this could also narrow the apparent survival gap between the groups, or worsen the apparent outcome of patients with normal karyotype. Fourth, newer prognostic markers, such as molecular abnormalities 21, 22 or flow cytometry abnormalities, 23,24 may modulate the importance of cytogenetics, but were not available for this study. Finally, we only used the disease karyotype closest to the time of SCT for analysis. It would be interesting to study the prevalence and impact of karyotypic evolution. However, because of the retrospective nature of this study, we could not systematically analyze karyotypic evolution for patients. Nevertheless, it seems reasonable to assume that the karyotype closest to the time of transplantation will be the one most important for transplantation outcome, and we therefore chose this karyotype for our analyses. Despite those limitations, the proposed cytogenetics grouping scheme has high prognostic significance for patients with MDS or AML arising from MDS who undergo SCT. It proved very successful in stratifying an independent cohort of patients. Indeed, in this study, patients in the two cytogenetics groups showed highly significant differences in overall and relapse free survival (RFS) after transplantation. In both the original study and the current analysis, adverse cytogenetics was the strongest prognostic factor for OS and RFS. Moreover, as in our earlier study, we found that this difference was entirely dependent on an increased risk of relapse in the adverse group. This was to be expected from the fact that cytogenetics are more a function of the disease itself than the host's ability to withstand transplantation. Importantly, we could also confirm that cytogenetics remain highly prognostically significant regardless of patient age, disease type or stage, and conditioning regimen intensity. The prognostic importance of cytogenetics after reduced intensity conditioning SCT argues that tumors with adverse cytogenetics are more resistant to the GVL effect than tumors with standard-risk cytogenetics, just as they are more resistant to conventional therapy.
As previously reported by Armand et al. 10 and Chang et al., 7 this study shows that therapy-related disease per se is not an adverse prognostic factor after SCT, after accounting for cytogenetics risk group (which otherwise may confound comparisons, since patients with therapy-related disease more often have adverse cytogenetics [25] [26] [27] [28] [29] ). This finding, now confirmed from several institutions, is important, as patients with therapy-related disease have a poor outcome with conventional therapy. 27, 30 The fact that this does not seem to be true for patients undergoing SCT supports (at least indirectly) the practice of offering SCT to patients with therapy-related disease early in their treatment course.
The validated transplantation-specific cytogenetics grouping scheme presented here can be used in the selection and counseling of SCT candidates. The fact that cytogenetics was the strongest prognostic factor in both our original study and the present ones argues for considering stratification of patients in clinical trials by cytogenetics, and our proposed scheme provides a means for doing so. Finally, this scheme may be used to calibrate transplantation outcomes among centers, under the new federal reporting rules.
